Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
BRIEFS
October 11, 2022
We are living in a time when many countries face heightened debt vulnerabilities. There is no international bankruptcy mechanism for countries that default on their external obligations. The objective of the international financial architecture—historically overseen by the IMF and its shareholders— ...
Blog Post
October 06, 2022
Despite alleged “lessons learned” from the COVID-19 pandemic about the need for early containment, getting the messaging right, and a swift rollout of diagnostics, vaccines, and therapeutics, we have seen the same blunders yet again in the monkeypox response, highlighting the inequities in the syste...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
Blog Post
October 04, 2022
The World Bank/IMF Annual Meetings begin next week—against a backdrop of mounting economic crises and uncertainty. How can we reduce global debt? Rethink the MDB/IMF system to address pressing issues like pandemics, climate change, and food security? Support poor countries where they need the most a...
Blog Post
September 26, 2022
Antimicrobial resistance is a major global problem. Today, drug resistant infections kill an estimated 1.27 million people per year, and low- and middle-income countries bear the brunt of AMR-related deaths and illness. Changing how we buy antimicrobials can help solve the problem.